MorphoSys Reports the Completion of Patient Enrollment in P-III Study (MANIFEST-2) of Pelabresib for Myelofibrosis
Shots:
- The company has completed the patient enrollment in the P-III study (MANIFEST-2) evaluating pelabresib (BET inhibitor) + ruxolitinib vs ruxolitinib alone in a ratio (1:1) in 400+ patients with myelofibrosis who have not prior treated with a JAK inhibitor. The results are expected at the end of 2023
- The 1EPs of the trial is the proportion of patients achieved a ≥35% reduction in spleen volume @24wk. & the 2EPs is the proportion of patients who achieved a ≥50% improvement in total symptom score @24wk.
- The trial was based on the P-II trial (MANIFEST) results. Additionally, patients enrollment in the P-III study (frontMIND) for tafasitamab is also complete in 1L diffuse large B-cell lymphoma & the results are expected in H2’25
Ref: morphosys | Image: morphosys
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
